



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)


[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SAG

## Chemical Properties

CAS No. :	912545-86-9
Formula:	C <sub>28</sub> H <sub>28</sub> ClN <sub>3</sub> O <sub>2</sub>
Molecular Weight:	490.06
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	SAG (Smoothed Agonist) is a Smo receptor agonist (EC <sub>50</sub> =3 nM) that is cell-permeable and selective. SAG regulates Smo activity by binding directly to the Smo helix and can activate the Hedgehog signaling pathway.
Targets(IC <sub>50</sub> )	Hedgehog/Smoothed,Smo
In vitro	<p><b>METHODS:</b> Embryonic stem cell ES were treated with SAG (0.5-1.25 μM) for 4-6 days and gene expression levels were measured using RT-qPCR.</p> <p><b>RESULTS:</b> Expression of Sim1, a post-mitotic V3 marker, was increased in all SAG-treated groups at all concentrations. The group treated with 0.5 μM SAG exhibited significantly higher levels of Nkx2.2 mRNA. Hb9 expression did not change significantly with SAG concentration at the given time points. [1]</p> <p><b>METHODS:</b> African green monkey kidney fibroblast-like cells, Cos-1, were treated with SAG (5-500 nM), and target protein expression levels were measured by Western Blot.</p> <p><b>RESULTS:</b> SAG inhibited cross-linking of ER-localized and post-ER forms of Smo-Myc3 to 125I-labeled PA cyclic amines in Cos-1 cells in a dose-dependent manner. cellular levels of Smo-Myc3 were not affected by agonist treatment. [2]</p>
In vivo	<p><b>METHODS:</b> To explore whether the SHH signaling pathway plays a protective role in anxiety by regulating mitochondrial homeostasis, SAG (10 mg/kg) was intraperitoneally injected into C57BL/6 mice on a high-fat diet every three days for twelve weeks.</p> <p><b>RESULTS:</b> SHH signaling is neuroprotective in obesity, and SAG alleviates anxiety-like behaviors by reducing mitochondrial breaks. [3]</p> <p><b>METHODS:</b> To study the effects on developing limbs, SAG (15-20 mg/kg in lactated Ringer's solution) was administered as a single intraperitoneal injection to pregnant C57BL/6J mice at gestational day (GD) 9.25.</p> <p><b>RESULTS:</b> The most prevalent effect of SAG was the dose-dependent induction of preaxial polydactyly; defects ranged from thumb width to duplication of both digitiform fingers on the preaxial side of the thumb. [4]</p>
Kinase Assay	In vitro Kinase Assays: Kinase assays for CDK1, CDK2 and GSK3-β are all carried out in a radiometric filter binding format. Assays for CDK5 are in DELFIA format and for CDKs 4 and 6 in ELISA format. For CDKs 1 and 2, the relevant CDK and 0.12 μg/mL Histone H1 are incubated in 20 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl <sub>2</sub> , 1 mM sodium orthovanadate, 1 mM DTT, 0.1 mg/mL BSA, 45 μM ATP (0.78 Ci/mmol) and different concentrations of AT7519 for 2 or 4 hours respectively. For GSK3-β, the relevant enzyme and 5 μM glycogen synthase peptide 2 along with 10 mM MOPS

pH 7.0, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% glycerol, 0.2 mM EDTA, 10 mM MgCl<sub>2</sub>, 0.01% β-mercaptoethanol, 15 μM ATP (2.31 Ci/mmol) and different concentrations of AT7519 are incubated for 3 hours. Assay reactions are stopped by adding an excess of orthophosphoric acid and filtered using Millipore MAPH filter plates. The plates are then washed, scintillant added and radioactivity measured by scintillation counting on a Packard TopCount. For CDK5, CDK5/p35 and 1 μM of a biotinylated Histone H1 peptide (Biotin-PKTPKKAKKL) are incubated in 25 mM Tris-HCl, pH 7.5, 2.5 mM MgCl<sub>2</sub>, 0.025% Brij-35, 0.1 mg/mL BSA, 1 mM DTT, 15 μM ATP and different concentrations of AT7519 for 30 minutes. Assay reactions are stopped using EDTA, transferred to Neutravidin-coated plates and phosphorylated peptide quantified by means of a rabbit phospho-cdk1 substrate polyclonal antibody and DELFIA europium-labelled anti-rabbit IgG secondary antibody using time-resolved fluorescence at λ<sub>ex</sub>=335 nm, λ<sub>em</sub>=620 nm. For CDK 4 and 6 assays, plates are coated with GST- pRb769-921 and blocked with Superblock. CDK4 or 6 is incubated with 15 mM MgCl<sub>2</sub>, 50 mM HEPES, pH 7.4, 1 mM DTT, 1 mM EGTA, pH 8.0, 0.02% Triton X-100, 2.5% DMSO and different concentrations of AT7519; the reaction is initiated by addition of ATP. After 30 minutes, reactions are stopped by the addition of 0.5 M EDTA pH 8.0. Plates are then washed and incubated for one hour with the primary antibody (anti- p-Rb Serine 780) diluted in Superblock followed by secondary antibody (alkaline phosphatase linked anti-rabbit) for a further hour. Plates are developed using the Attophos system and fluorescence read on a Spectramax Gemini plate reader at excitation 450 nm and emission 580 nm. In all cases, IC<sub>50</sub> values are calculated from replicate curves, using GraphPad Prism software.

### Solubility Information

Solubility	DMSO: 55 mg/mL (112.23 mM), Heating is recommended. Ethanol: 40 mg/mL (75.97 mM), Heating is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0406 mL	10.2028 mL	20.4057 mL
5 mM	0.4081 mL	2.0406 mL	4.0811 mL
10 mM	0.2041 mL	1.0203 mL	2.0406 mL
50 mM	0.0408 mL	0.2041 mL	0.4081 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Xu H, et al. Directed Differentiation of V3 Interneurons from Mouse Embryonic Stem Cells. *Stem Cells Dev.* 2015 Nov 15;24(22):2723-32.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481